Candidate selection
Accurate human dose predictions to support clinical success
EARLY CONFIRMATION
The candidate falls within
the therapeutic window
NOISE REDUCTION
Mathematical modelling eliminates
murine metabolic biases.
HUMAN-TRANSLATABLE
Objective data.
MORE ACCURATE
CLINICAL STARTING
DOSE
First-in-Human trial.
HIGHER
PROBABILITY OF
CLINICAL SUCCESS
Do you have a compound in this phase?
Which TAD services can help you to move forward?
Fully document the PK/PD and general efficacy properties for regulatory filings
Prepare a solid rock PK/PD on the therapeutic efficacy of your drugs using the TADhuMouse®. An integrated tool to predict the speed of action, Total Human Dose to inform Phase I and even, liabilities because of resistance and identification of optimal partners for combination.
Main outcomes
Parasite Stage susceptibility
Which stage is most sensitive to treatment?
Maximum parasite clearance
Is it a fast, slow or very slow treatment in vivo?
Preliminary oral PK
What is the best schedule of treatment and dose range to optimally test your treatment in TADhuMouse® in vivo?
Tolerability and potential adverse
effects
How is the best way to analyze the treatment in TADhuMouse ® in vivo?
Benchmarking with standard
antimalarials
Where the new treatment maps in efficacy compared to standard antimalarials?
Full PK/PD evaluation TADhuMouse®
Help define realistic Total Human Dose Prediction
PK/Tox liabilities because of hemotoxicity
(i.e., G6PD)
Are all G6PD genotypes susceptible and, at what exposures?
Irresistible Test
What mutations arise and what is their impact on susceptibility to treatment?
Efficacy against field-strains
Impact of regional strains on Total Human Dose Prediction
Total Human Optimal dosing
Realistic Total Human Dose Prediction
Define combination strategy
Test alternatives using the Full PK/PD and TADmaps®
